Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc., which is a subsidiary) on December 14, 2021. The report details the Board of Directors' approval of performance-based cash bonus structures for the 2022 fiscal year for employees across the Company, Curation Foods, Inc., and Lifecore Biomedical, Inc.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on executive compensation criteria.
Material Changes
The primary material change reported is the establishment of new bonus performance criteria for the 2022 fiscal year. Bonuses are tied to adjusted EBITDA goals with the following thresholds:
- Company and Curation Foods: No bonus is payable if adjusted EBITDA is 93.3% or less of the target.
- Lifecore Biomedical: No bonus is payable if adjusted EBITDA is 94% or less of the target.
- Payout Range: Bonuses range from 0% to 200% of the target bonus based on actual achievement.
- Eligibility: Participants must be employed at the end of the 2022 fiscal year to receive any bonus.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on market outlook, or discussion of specific risks and contingencies beyond the operational requirement that employees remain with the company through the end of the fiscal year to qualify for compensation.
Investor Verification Checklist
- Verify the specific adjusted EBITDA targets for Landec, Curation Foods, and Lifecore for the 2022 fiscal year, as these are not disclosed in this filing.
- Confirm the total potential bonus pool exposure for named executive officers.
- Review subsequent filings to determine if the 2022 EBITDA targets were met and bonuses were awarded.